SESSION TITLE: Respiratory Infections
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Tuesday, October 28, 2014 at 11:00 AM - 12:15 PM
PURPOSE: Purpose: Mycobacterium abscessus complex is the second most common organism isolated from patients with nontuberculous mycobacterial (NTM) lung disease in South Korea. This study aimed to compare clinical features and treatment outcomes of M. abscessus and M. massiliense lung disease.
METHODS: Methods: We retrospectively identified stored clinical isolates of M. abscessus complex as either M. abscessus or M. massiliense and reviewed medical records to compare clinical characteristics and treatment responses. All patients were treated empirically over several months with multidrug regimens, including a macrolide and one or more parenteral agents.
RESULTS: Results: Of the 249 patient isolates tested, 128 (59 with M. abscessus and 69 with M. massiliense) met the American Thoracic Society diagnostic criteria for NTM pulmonary disease, and treatment outcomes were analyzed in 48 patients (26 with M. abscessus and 22 with M. massiliense). The clinical and radiologic findings were similar between the two groups, except for the ratio of cavitary lesions. Although the durations of parenteral and total treatment were significantly shorter in patients with M. massiliense than in those with M. abscessus (7.4 months vs 4.7 months, P = .006, and 16.3 months vs 12.1 months, P = .043), the treatment success rate was significantly higher in patients with M. massiliense (95.5%) than in M. abscessus cases (42.3%, P<.001).
CONCLUSIONS: Conclusion:Patients with M. massiliense pulmonary infection respond better to antibiotic therapy than those with M. abscessus infection. A shortened duration of treatment may be sufficient for M. massiliense pulmonary infection.
CLINICAL IMPLICATIONS: Even though the treatment duration was significantly shorter, the treatment response was significantly better in patients with M. massiliense infection than in those with M. abscessus infection. A shortened duration of treatment may be sufficient for M. massiliense pulmonary infection.
DISCLOSURE: The following authors have nothing to disclose: Jiwon Lyu, Bum-Joon Kim, Byeong-Joon Kim, Jin Woo Song, Chang-Min Choi, Sang Do Lee, Woo Sung Kim, Dong Soon Kim, Tae Sun Shim
No Product/Research Disclosure Information